Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1991 1
1992 1
1993 1
1994 2
1995 2
1996 1
1997 2
1999 1
2000 1
2003 2
2004 1
2006 4
2007 2
2009 1
2010 1
2011 1
2012 3
2013 2
2014 1
2015 2
2016 2
2017 2
2018 1
2019 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Hormone-resistant breast carcinoma"
Page 1
Single cell profiling of female breast fibroadenoma reveals distinct epithelial cell compositions and therapeutic targets.
Chen Z, Zhang Y, Li W, Gao C, Huang F, Cheng L, Jin M, Xu X, Huang J. Chen Z, et al. Nat Commun. 2023 Jun 16;14(1):3469. doi: 10.1038/s41467-023-39059-3. Nat Commun. 2023. PMID: 37328469 Free PMC article.
Here, using single-cell RNA sequencing of human FAs and normal breast tissues, we observe distinct cellular composition and epithelial structural changes in FAs. Interestingly, epithelial cells exhibit hormone-responsive functional signatures and synchronous activat …
Here, using single-cell RNA sequencing of human FAs and normal breast tissues, we observe distinct cellular composition and ep …
Chemotherapy of breast cancer: a historical perspective.
Hortobagyi GN. Hortobagyi GN. Semin Oncol. 1997 Oct;24(5 Suppl 17):S17-1-S17-4. Semin Oncol. 1997. PMID: 9374083 Review.
Over the last 30 years, our knowledge about the clinical behavior of breast cancer has increased substantially. Our ability to identify several prognostic subgroups and predict hormone-responsive and hormone-resistant disease has led to more rational u …
Over the last 30 years, our knowledge about the clinical behavior of breast cancer has increased substantially. Our ability to identi …
Selecting endocrine therapy for breast cancer: what role does HER-2/neu status play?
Prowell TM, Armstrong DK. Prowell TM, et al. Semin Oncol. 2006 Dec;33(6):681-7. doi: 10.1053/j.seminoncol.2006.08.016. Semin Oncol. 2006. PMID: 17145348 Review.
Most women with breast cancer that overexpresses either estrogen (ER+) or progesterone receptors (PR+) will be treated with an endocrine agent. Although ER and PR are the only validated predictive markers of response to hormonal therapy, many women with hormone rece …
Most women with breast cancer that overexpresses either estrogen (ER+) or progesterone receptors (PR+) will be treated with an endocr …
Correlations of DKK1 with incidence and prognosis of breast cancer.
Sun W, Shang J, Zhang J, Chen S, Hao M. Sun W, et al. J BUON. 2019 Jan-Feb;24(1):26-32. J BUON. 2019. PMID: 30941948 Free article.
RESULTS: DKK1 expression was confirmed in hormone-resistant breast cancer cell lines SK and MDA-MB231. DKK1 expression in breast cancer was associated with cytoplasm/nuclear beta-catenin (p<0.01). ...CONCLUSION: Both DKK1 and beta-catenin may be imp …
RESULTS: DKK1 expression was confirmed in hormone-resistant breast cancer cell lines SK and MDA-MB231. DKK1 expression …
How do breast cancers become hormone resistant?
Horwitz KB. Horwitz KB. J Steroid Biochem Mol Biol. 1994 Jun;49(4-6):295-302. doi: 10.1016/0960-0760(94)90271-2. J Steroid Biochem Mol Biol. 1994. PMID: 8043492 Review.
We propose that the molecular heterogeneity of estrogen receptors (ER) in breast tumor cells characterized by the presence of mutant receptor forms, generates the cellular heterogeneity evident when progesterone receptor (PR) or DNA ploidy are analyzed in cell subpopulatio …
We propose that the molecular heterogeneity of estrogen receptors (ER) in breast tumor cells characterized by the presence of mutant …
Biology of female sex hormone action in relation to contraceptive agents and neoplasia.
King RJ. King RJ. Contraception. 1991 Jun;43(6):527-42. doi: 10.1016/0010-7824(91)90002-w. Contraception. 1991. PMID: 1651204 Review.
This review of the action of estrogens and progestagens, the steroids in oral contraceptives, on cells in the endometrium, breast, ovary, cervix and other tissues, regarding possible causative role in cancer development focuses on the level of steroid receptors and obse …
This review of the action of estrogens and progestagens, the steroids in oral contraceptives, on cells in the endometrium, breast, ov …
Natural interferon-alpha activity in hormone-sensitive, hormone-resistant and autonomous human breast-cancer cell lines.
Iacopino F, Robustelli della Cuna G, Sica G. Iacopino F, et al. Int J Cancer. 1997 Jun 11;71(6):1103-8. doi: 10.1002/(sici)1097-0215(19970611)71:6<1103::aid-ijc29>3.0.co;2-c. Int J Cancer. 1997. PMID: 9185717
This study explored the activity of natural interferon-alpha (nIFN-alpha) in regulating cell growth of 6 breast-cancer cell lines. The anti-proliferative effect of the combination nIFN-alpha and tamoxifen (TAM) or medroxyprogesterone acetate (MPA) in CG-5 estrogen-sensitiv …
This study explored the activity of natural interferon-alpha (nIFN-alpha) in regulating cell growth of 6 breast-cancer cell lines. Th …
Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-alpha in Hormone-Resistant Breast Cancers.
Singh K, Munuganti RSN, Lallous N, Dalal K, Yoon JS, Sharma A, Yamazaki T, Cherkasov A, Rennie PS. Singh K, et al. Int J Mol Sci. 2018 Feb 15;19(2):579. doi: 10.3390/ijms19020579. Int J Mol Sci. 2018. PMID: 29462880 Free PMC article.
Estrogen receptor-alpha positive (ERalpha+) breast cancers represent 75% of all invasive breast cancer cases, while de novo or acquired resistance to ER-directed therapy is also on the rise. ...Notably, the identified lead compound successfully inhibits known consti …
Estrogen receptor-alpha positive (ERalpha+) breast cancers represent 75% of all invasive breast cancer cases, while de novo or …
Can hormone "resistant" breast cancer cells be inappropriately stimulated by tamoxifen?
Horwitz KB. Horwitz KB. Ann N Y Acad Sci. 1993 Jun 11;684:63-74. doi: 10.1111/j.1749-6632.1993.tb32271.x. Ann N Y Acad Sci. 1993. PMID: 8317847 Review.
We find that heterogeneity of PR and DNA ploidy reflects existence of mixed subpopulations of breast cancer cells that are substantially remodeled under the influence of tamoxifen. ...Our data also suggest that the use of tamoxifen as a chemopreventant in women at high ris …
We find that heterogeneity of PR and DNA ploidy reflects existence of mixed subpopulations of breast cancer cells that are substantia …
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
Kikawa Y, Kotake T, Tsuyuki S, Kang Y, Takahara S, Fujimoto Y, Yamashiro H, Yoshibayashi H, Takada M, Yasuoka R, Nakatsukasa K, Yamagami K, Suwa H, Okuno T, Nakayama I, Kato T, Ogura N, Moriguchi Y, Ishiguro H, Kagimura T, Taguchi T, Sugie T, Toi M. Kikawa Y, et al. Breast Cancer. 2022 Sep;29(5):796-807. doi: 10.1007/s12282-022-01357-x. Epub 2022 Apr 23. Breast Cancer. 2022. PMID: 35460066
This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocrine-resistant advanced or metastatic breast cancer (AMBC) in the real-world clinical setting. METHODS: This multi-institutional prospe …
This study aimed to investigate the effectiveness of eribulin administration as first- and second-line chemotherapy in patients with endocri …
37 results